| My Account | Subscribe | Contact Us | Donate |
Home
- Kris Freeman Skis for Olympic Gold
- Good Insulin Injection Practices
- Etiquette for People without Diabetes
- Diabetes Technology and Intimacy
- An American in the UK: Healthcare for Type 1s
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Medications Research Articles
Diabetes Medications Research Article Archives
December 2009
A 20-year study that tracked 704 women from before their first pregnancy onward suggests that the first year mothers breastfeed, they reduce their risk of acquiring type 2 diabetes within the next 15 years by 15 percent. Each subsequent year of breastfeeding further reduces the risk by 15 percent. For example, a mother who has two children and breastfeeds each for a year could enjoy a 30 percent reduction in her risk of type 2 over a 15-year period.
2 comments - Posted Dec 25, 2009
FRIDAY, Dec. 18 (HealthDay News) -- Blacks tend to carry around less of a particularly unhealthy type of abdominal fat than whites, even though they suffer more from obesity-linked illness, researchers report.
0 comments - Posted Dec 23, 2009
WORCESTER, Mass., Dec 3, 2009 (GlobeNewswire via COMTEX News Network) -- Published in the journal Diabetes, Obesity and Metabolism, an independent review of clinical trials of Generex Oral-lyn(TM) shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously.
6 comments - Posted Dec 9, 2009
A Swedish biotechnology company, TikoMed AB, has received notice that the U.S. Food and Drug Administration is granting orphan drug designation to its IBsolvMIR® drug for preventing the rejection of transplanted pancreatic islet cells in type 1 patients.
0 comments - Posted Dec 4, 2009
October 2009
A South African university pharmacologist has found that simultaneous consumption of metformin and grapefruit juice raises lactic acid to dangerous levels in rats (and conceivably in people) with type 2 diabetes. Too much acid in the blood can cause low pH levels that interfere with the body's metabolic functions. Conceivably, says Dr. Peter Owira, a pharmacologist at the University of KawZulu-Natal, such low levels could be fatal.
4 comments - Posted Oct 26, 2009
So close, and yet so far. It looks like there will be no marketing partnership for MannKind's ultra rapid-acting insulin product Afresa anytime soon. The company had planned to enter into a deal with a large pharmaceutical company by the end of this year, but now approval from the Food and Drug Administration (FDA) for their inhaled insulin won't be until January 2010, at the earliest.
3 comments - Posted Oct 8, 2009
The demise of Fen-phen dealt a body blow to hopes for an obesity pill that is actually effective. Unfortunately, the fen in Fen-phen, fenfluramine, caused grave pulmonary hypertension and heart valve problems. The phen part of the drug, though, was apparently just an innocent bystander. And now phen (phentermine) has resurfaced in a new pill that has posted some amazing results in Phase III clinical trials. Patients who were treated for 56 weeks with the new drug, Qnexa, lost an average of 14.7 percent of their weight, or 37 pounds.
8 comments - Posted Oct 7, 2009
A study coming out in the November issue of the Clinical Journal of the American Society of Nephrology is reporting that type 2 men whose blood contained a high count of eosinophils, a sign of allergic inflammation, also had albumin in their urine, which is an early indication of kidney disease. Eosinophils are white blood cells that increase in number during an allergic reaction. Albumin is a protein in the blood that helps regulate blood volume and acts as a carrier for other molecules. Albumin is not normally found in the urine, however, because when healthy kidneys filter the blood, they retain what the body needs (like proteins) and allow only smaller "impurities" into the urine. But during diabetes, too much blood sugar can damage the filtering structures of the kidneys, causing them to thicken and become scarred. Eventually, they begin to leak, and protein (albumin) begins to pass into the urine.
0 comments - Posted Oct 6, 2009
The enthusiasm for inhaled insulin has waned, to say the least, since Exubera was pulled off the market by Pfizer. Following the Exubera debacle, the development of two other inhaled insulins (AIR by Eli Lilly and Alkermes, and AERx by Novo Nordisk) was halted as well.
13 comments - Posted Oct 5, 2009
September 2009
Clinical trials are conducted before a new drug is released for sale, in part to test for bad things that might happen when people take it. But clinical trials don't involve all that many people: several thousand at the most. After the clinical trials are successfully completed, however, the drug is sold to millions upon millions. Merck's sales of Januvia and Janumet, for example, totaled over a billion dollars in the first six months of this year alone.
0 comments - Posted Sep 30, 2009
Metformin has always been the old reliable for treating new onset type 2 diabetes, but it's beginning to look like it's got a new calling as a cancer treatment. Diabetes Health recently reported on the fact that metformin reduces a type 2 person's risk of pancreatic cancer by up to 62 percent. It's also been observed that people with type 2 who take metformin have a much lower cancer incidence than those who don't. Now it appears that metformin can help with breast cancer treatment as well. A study of mice with breast cancer generated from human breast cancer cells has found that they remained tumor-free for nearly three months on metformin combined with doxorubicin, a standard cancer chemotherapy. In mice given only the doxorubicin, the tumors recurred.
1 comment - Posted Sep 25, 2009
August 2009
A Japanese company whose biggest moneymaker is the sale of synthetic fabrics announced a few days ago that it has developed an insulin nasal spray for people with diabetes. The news brought an investor surge that lifted the value of its stocks by 10 percent.
0 comments - Posted Aug 28, 2009
A new glucagon-like peptide-1 (GLP-1) analog for type 2s that might require dosing only once a month is now in pre-clinical (animal) studies. GLP-1, which increases insulin secretion from the pancreas, is a mighty helpful molecule, but with a sadly brief lifespan. It's broken down in the body within minutes by the enzyme DPP-4. That's why drugs like Merck's Januvia, a DPP-4 inhibitor, is effective: blocking DPP-4 subsequently increases the amount of GLP-1 in the system.
0 comments - Posted Aug 25, 2009
July 2009
May 5 - Ann Arbor, MI - In the first study of the effects of statins on the concentrations of both low-density lipoprotein cholesterol (LDL-C; known as the "bad" cholesterol) and low-density lipoprotein particles (LDL-P) in patients with metabolic syndrome, it was shown that even though the statins lowered the concentrations of LDL-C to target levels, the patients retained considerable residual risk for cardiovascular events because LDL-P concentrations were not reduced to a similar extent. A pre-print version of the study in Diabetes Care is available online at http://dx.doi.org/10.2337/dc08-1681, and the final version will be available in print in the June 2009 issue, as well as online at the same URL.
0 comments - Posted Jul 29, 2009
According to results of a phase II clinical trial at the University of Texas Medical School, a low dose of oral interferon alpha can preserve pancreatic beta cell function in newly diagnosed type 1 diabetes patients. Interferons are proteins produced by the cells of the immune system in response to challenges like a virus or a tumor cell. They work by inhibiting viral replication in the host cell, activating natural killer cells, and increasing the activity of other immune system cells such as lymphocytes.
0 comments - Posted Jul 24, 2009
An analysis of ten trials involving statin therapy among 70,000 participants has led an international team of cardiologists to recommend that that the cholesterol-lowering drugs be prescribed for people who do not have heart disease.
2 comments - Posted Jul 15, 2009
Scientists have identified five genetic biomarkers that predict how well a type 2 patient will respond to the drug Actos. Their work could be the first step toward a system that would allow doctors to predetermine which drugs will best help each person with diabetes.
0 comments - Posted Jul 3, 2009
Genentech, a bioscience firm famous for its development of antibodies designed to combat cancer, has entered a $350 million agreement with Bayhill Therapeutics to assist in development of BHT-3021, a drug that treats type 1 diabetes by reducing or stopping immune system attacks on pancreatic beta cells.
2 comments - Posted Jul 1, 2009
June 2009
Drug companies spend billions of dollars on research, and it's obvious that they spend more billions on advertising. Well, according to the New York Times, they spend the most billions on giving nice things to doctors: pens, samples, banquets, trips, and educational opportunities among them. For doctors, in fact, there is a free lunch: Pharma companies spend as much as a billion a year just on lunches for doctors. And over 90 percent of doctors have accepted at least some of this largesse from the industry.
5 comments - Posted Jun 12, 2009
Patients with type 2 diabetes reduced their risk of having a foot amputated by 36 percent when they took fenofibrate, a drug designed to lower blood fat levels.
0 comments - Posted Jun 12, 2009
Spanish university researchers have isolated a new species of bacteria-which they found in sewer sludge-that is able to break down cholesterol.
0 comments - Posted Jun 4, 2009
CRx-401, an insulin sensitizer intended to assist metformin in type 2 diabetes therapy, has successfully completed a Phase 2 clinical trial in which patients taking it saw their fasting plasma glucose drop by 12 mg/dl after 90 days.
1 comment - Posted Jun 3, 2009
May 2009
In a recent 16-week randomized, open-label pilot study, 169 patients were randomized to receive Welchol (n=57), Januvia (n=56), or Avandia (n=56).1 The results demonstrated that Welchol (colesevelam HCl) significantly improved glycemic control and reduced mean LDL cholesterol (LDL-C) when added to metformin monotherapy in patients with type 2 diabetes. In the study, Januvia® (sitagliptin) and Avandia® (rosiglitazone) also significantly improved glycemic control, but LDL-C increased in patients on both of these treatment regimens.
0 comments - Posted May 29, 2009
Humanin (HN) is a mitochondrial peptide* that in some research has shown the ability to protect against the death of neurons, the devastating consequence of diseases like Alzheimer's. According to the leader of a research team at the Albert Einstein College of Medicine at Yeshiva University in the Bronx, however, it also significantly improves the insulin sensitivity of diabetic rats and sharply drops their glucose levels.
2 comments - Posted May 20, 2009
Dental researchers are reporting that resolvins, products derived from omega-3 fatty acids, may have the ability to restore the soft tissue and even bone lost in periodontal (gum) disease.
0 comments - Posted May 7, 2009
The European Union's drug regulation agency has recommended that the EU approve the marketing of "Victoza" (liraglutide), a type 2 drug developed by Novo Nordisk.
2 comments - Posted May 6, 2009
Voglibose*, a generic drug often used in combination with sulfonylureas to control blood glucose levels, appears to delay or even prevent the onset of diabetes in people who are predisposed to the disease.
5 comments - Posted May 1, 2009
April 2009
Results from DURATION-2, a 26-week test comparing the diabetic drugs Januvia, Actos, and experimental long-acting Byetta (Byetta LAR) show that Byetta produced lower A1c's and more weight loss than the other two drugs.
5 comments - Posted Apr 15, 2009
Buoyed by its recent successful phase 1 human clinical trial of a patch that delivers basal insulin through the skin, Atlanta-based Altea Therapeutics says it will work with Eli Lilly and Company and Amylin Pharmaceuticals, Inc., to develop a daily transdermal patch that deliver sustained levels of Byetta (exenatide). The patch, in a 12- and a 24-hour form, will use the company's proprietary PassPort Transdermal Delivery System. Lilly and Amylin will fund all development, manufacturing, and marketing activities for the product.
2 comments - Posted Apr 7, 2009
Last week we published an article about how the CDC says too many people are still smoking. The federal government has a Healthy People 2010 goal of reducing adult smoking rates to 12 percent or less by 2010. Of the 50 states, only Utah has thus far achieved that goal.
1 comment - Posted Apr 2, 2009
March 2009
AR9281, a drug developed by the University of California at Davis and now under further development by a California-based pharmaceutical company, has entered Phase II of human clinical trials.
1 comment - Posted Mar 27, 2009
New guidelines from the U.S. Preventive Services Task Force state that daily low doses of aspirin-75 milligrams to 81 milligrams-are as effective as higher doses (100+ milligrams) in preventing heart attacks among men and strokes among women.
3 comments - Posted Mar 26, 2009
Physicians who treat people with type 2 diabetes face difficult choices when selecting the best medical therapy for each patient. The decision process is further complicated by the fact that because type 2 diabetes is a progressive disease, therapeutic agents that were initially successful may fail five or ten years later.
148 comments - Posted Mar 20, 2009
Researchers funded by the Juvenile Diabetes Research Foundation have found two chemical compounds that can trigger the growth of insulin-producing beta cells in the pancreas. The discovery could become the basis for medicines designed to regenerate the pancreas in people with type 1 diabetes.
9 comments - Posted Mar 11, 2009
A complex sugar derived from glucose during the body’s metabolic processes could be a way to reliably detect a pre-diabetes condition, say researchers at the Johns Hopkins University School of Medicine in Baltimore. If it does, the “biomarker” (an indicator of an organism’s state of health) could provide enough early warning that patients nearing the onset of type 2 diabetes could take steps to slow or even halt it through lifestyle changes.
1 comment - Posted Mar 3, 2009
February 2009
DM-99, a drug under development by the Canadian drug company DiaMedica, Inc., has just finished a phase 2a "proof of concept" trial with 40 type 2 patients in Europe. Although the company did not release performance figures from the trial, it found them sufficiently encouraging to move further into phase 2 testing.
0 comments - Posted Feb 26, 2009
A report in the February 4, 2009, issue of Cell Metabolism says that babies born with neonatal diabetes might be able to avoid irreversible damage to the pancreas if doctors treat them quickly with sulfonylureas rather than insulin.
0 comments - Posted Feb 25, 2009
Georgia researchers believe that a powerful enzyme that inhibits or modifies immune system response could be the basis for a vaccine administered to children at high risk for developing type 1 diabetes.
0 comments - Posted Feb 25, 2009
Avanafil, a pill that may permit diabetic men who are experiencing erectile dysfunction to engage in intercourse without the restrictions on food or alcoholic intake associated with other ED treatments, is entering a second phase 3 study-the crucial step before a drug manufacturer seeks FDA or European approval to market.
5 comments - Posted Feb 24, 2009
Data from a phase 3 study of the Novo Nordisk drug liraglutide shows that when it is used in combination with glimepiride, it is more effective at reducing A1c's than glimepiride by itself or glimepiride in combination with the drug rosiglitazone.
0 comments - Posted Feb 19, 2009
By introducing a protein called cdk6 into human insulin-producing adult beta cells via a virus, University of Pittsburgh School of Medicine researchers have induced the cells to replicate "robustly." Previously, scientists believed that beta cells could be induced to regenerate slowly at best, and usually not at all.
0 comments - Posted Feb 5, 2009
January 2009
Syracuse University chemist Robert Doyle has taken out a patent on something that has long been a Holy Grail for insulin suppliers and users: a reliable way to take insulin orally instead of with a needle.
4 comments - Posted Jan 28, 2009
We first reported on salsalate, an aspirin-like drug discovered in the nineteenth century, last October. At that time, researchers at the Joslin Diabetes Center in Boston discovered that it appears to reduce inflammation and lower blood glucose in people with type 2 diabetes.
2 comments - Posted Jan 27, 2009
For patients who suffer frequent sharp abdominal pain from chronic pancreatitis, antioxidants may offer effective pain relief, according to a study recently published in Gastroenterology, the journal of the American Gastroenterological Association Institute.
5 comments - Posted Jan 23, 2009
Hearts in the medical community beat with considerable excitement at the discovery of leptin in 1994. A hormone produced by fat, leptin has a very useful talent: it tells the brain when to stop eating. So hopes were high that leptin would become the basis of an anti-obesity treatment. What could be simpler than to dose an obese person with a hormone that says, "You're not hungry any more, and you want to stop eating."
0 comments - Posted Jan 22, 2009
According to biologists at the Baylor College of Medicine, limiting the copies of a gene that produces a protein affecting organ development serves to decrease fat cell size in mice, enhance their responsiveness to insulin, and increase their energy level.
0 comments - Posted Jan 14, 2009
December 2008
A study of the effectiveness of the drug terbutaline on controlling nighttime hypoglycemia in people with type 1 diabetes indicates that it may be a safe and useful treatment with no ill effects.
5 comments - Posted Dec 29, 2008
Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.
0 comments - Posted Dec 22, 2008
November 2008
Researchers at the University of California, San Francisco, have found that two drugs used to treat cancer can prevent or cure type 1 diabetes in mice.
7 comments - Posted Nov 24, 2008
Metformin, the tried-and-true diabetes drug that is prescribed to many type 2s when they are first diagnosed, may decrease the risk of death from cardiovascular disease. That's the conclusion of a meta-analysis by researchers at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.
0 comments - Posted Nov 3, 2008
The annual cost for drugs to treat type 2 diabetes nearly doubled between 2001 and 20, skyrocketing from $6.7 billion in 2001 to $12.5 billion six years later, according to researchers from Stanford University and the University of Chicago.
0 comments - Posted Nov 3, 2008
October 2008
Novo Nordisk recently announced results from its LEAD 6 study showing that once daily liraglutide was significantly more effective at improving blood glucose control (as measured by A1c) than exenatide, a GLP-1 mimetic administered twice daily.
4 comments - Posted Oct 27, 2008
An experimental exenatide (Byetta)-like drug called liraglutide has shown the ability to enhance insulin and glucagon production and suppress appetite in type 2 patients, according to a report in the British medical journal The Lancet.
0 comments - Posted Oct 13, 2008
An aspirin-like drug discovered 132 years ago may prove to be a powerful weapon against type 2 diabetes.
3 comments - Posted Oct 13, 2008
September 2008
A Canadian clinical study has delivered a double dose of good news for proponents of exenatide (sold commercially as Byetta), a drug used by more than 700,000 Americans to control blood glucose, ease food cravings, and, incidentally, lose weight.
3 comments - Posted Sep 11, 2008
July 2008
You’ve got type 2 diabetes. A few years ago, you started using a long-acting insulin once a day, and your fasting glucose levels and your A1c came down. But now your A1c is creeping back up. Your doctor tells you that you need to add a mealtime insulin to your plan.
2 comments - Posted Jul 31, 2008
The Food and Drug Administration is considering a requirement that before receiving agency approval, new diabetes treatment drugs must not only lower blood sugar levels, but also demonstrate a positive effect on heart disease and lifespan.
1 comment - Posted Jul 3, 2008
October 2007
According to Greek researchers, Actos and Avandia were behind a tripling of the cost of medicines used to treat Athenians with type 2 diabetes over the past eight years.
0 comments - Posted Oct 10, 2007
September 2006
January 2006
It was the belle of the ball at last summer’s ADA Scientific Sessions in San Diego. Now it appears that muraglitazar (Pargluva) is clinging to life after a scathing report recently published by the Journal of the American Medical Association.
0 comments - Posted Jan 1, 2006
September 1999
Two new drugs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes. In clinical trials, Avandia (rosiglitazone maleate) and ACTOS (pioglitazone hydrochloride) lowered blood sugars an average of 76 mg/dl and 95 mg/dl respectively, when compared to a placebo.
0 comments - Posted Sep 1, 1999